Summary

The biosimilars market is projected to reach USD 70.79 billion by 2036 from an estimated USD 37.39 billion in 2026, registering a CAGR of 6.6% during the forecast period. Market growth is primarily driven by increasing awareness and education regarding the safety, efficacy, and interchangeability of biosimilars, resulting in increased acceptance among healthcare providers and patients. In parallel, favorable insurance coverage and reimbursement policies across public and private healthcare systems are supporting broader adoption by improving the affordability and accessibility of biosimilar therapies. The growing need to reduce healthcare expenditure and expand patient access to cost-effective biologic treatments is further accelerating demand.

However, the market's expansion is constrained by the increasing complexity of biosimilar development and manufacturing, which requires sophisticated technologies, stringent quality controls, and substantial investment. In addition, the growing number of biosimilars competing within the same therapeutic categories is intensifying price competition and margin pressure, particularly in mature markets. These factors are expected to moderate market growth over the forecast period despite continued expansion in biosimilar utilization and market penetration.
The monoclonal antibodies segment is expected to witness the highest growth rate during the study period.
By drug class, the monoclonal antibodies (mAbs) segment is expected to register the highest CAGR during the forecast period, supported by the extensive use of biologics such as Infliximab, Rituximab, Adalimumab, Trastuzumab, Pembrolizumab, Dupilumab, Ustekinumab, Risankizumab, Daratumumab, Nivolumab, and other mAbs across oncology, autoimmune diseases, chronic inflammatory conditions, and selected infectious diseases. The growing prevalence of cancer and autoimmune disorders, combined with an expanding eligible patient population and increasing utilization of biologic therapies, is expected to strengthen demand for mAb biosimilars. In addition, the anticipated loss of patent and regulatory exclusivity for several high-value reference biologics will create opportunities for biosimilar manufacturers to enter large and established therapeutic markets.

mAbs are widely used in the management of cancer, rheumatoid arthritis, psoriasis, inflammatory bowel disease, and other chronic and potentially life-threatening conditions, with demand further supported by an aging population and the increasing burden of chronic diseases. The availability of biosimilar alternatives can reduce treatment costs, expand patient access, and encourage greater utilization of biologic therapies, particularly in cost-sensitive healthcare systems. Over the next decade, the expected loss of exclusivity of multiple high-value mAbs is likely to attract additional pharmaceutical and biotechnology companies, intensifying competition and expanding the global biosimilar landscape. The broad therapeutic applicability and substantial commercial value of mAb reference products, particularly across oncology and immunology, are therefore expected to make monoclonal antibody biosimilars a major contributor to market growth through 2036.

The US is expected to register the highest CAGR during the forecast period.

By country, the US is expected to register the highest CAGR in the global biosimilars market between 2026 and 2036, supported by the growing number of biosimilar launches, loss of exclusivity of high-value biologics, increasing payer acceptance, and continued development of the regulatory framework under the Biologics Price Competition and Innovation Act (BPCIA). The US market is entering a period of significant biosimilar expansion as additional reference biologics lose patent and regulatory exclusivity, creating opportunities across high-value therapeutic areas such as oncology, immunology, ophthalmology, and endocrinology.

The commercialization of biosimilars to major biologics, including Stelara (ustekinumab), Eylea (aflibercept), and other high-value reference products, is expected to substantially expand the addressable market during the forecast period. The US has already demonstrated strong competitive activity following the introduction of biosimilars to Humira (adalimumab) beginning in 2023, with multiple manufacturers, including Amgen, Boehringer Ingelheim, and Sandoz, entering the market. Increasing competition among manufacturers has contributed to lower prices and broader payer and formulary access, while interchangeability designations for selected biosimilars can further facilitate substitution and adoption.

In addition, growing awareness among physicians, patients, payers, and healthcare providers, together with federal initiatives aimed at improving affordability and reducing healthcare expenditure, is expected to support continued biosimilar uptake. As the number of interchangeable biosimilars increases and stakeholders gain greater experience with switching between reference biologics and biosimilars, adoption is expected to accelerate. These factors, combined with the large US biologics market, high healthcare expenditure, substantial eligible patient population, and continued influx of biosimilar competitors, are expected to position the US as one of the fastest-growing and most commercially attractive markets for biosimilars through 2036.

The primary interviews conducted for this report can be categorized as follows:

・By Respondent: Supply Side (70%) and Demand Side (30%)
・By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
・By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and Middle East & Africa (5%)
List of Key Companies Profiled in the Report:
Key players in the biosimilars market include Sandoz Group AG (Switzerland), Pfizer Inc. (US), Amgen Inc. (US), Celltrion Inc. (South Korea), Biocon Limited (India), Dr. Reddy’s Laboratories Ltd. (India), Eli Lilly and Company (US), Teva Pharmaceutical Industries Ltd. (Israel), Fresenius Kabi AG (Germany), Stada Arzneimittel AG (Germany), Boehringer Ingelheim International GmbH (Germany), Samsung Bioepis Co., Ltd. (South Korea), Amneal Pharmaceuticals, Inc. (US), Bio-Thera Solutions, Ltd. (China), Aprogen Inc. (South Korea), Shanghai Henlius Biotech, Inc. (China), and Alvotech (Iceland).
Research Coverage:
This research report categorizes the biosimilars market by drug class (Monoclonal Antibodies, Granulocyte Colony-Stimulating Factor (G-CSF), Insulin, Erythropoietin, Recombinant Human Growth Hormone, Etanercept, Follitropin, Teriparatide, Interferons, Anticoagulants, Aflibercept, GLP-1 Agonist, and Other Drug Classes), indication (Oncology, Inflammatory & Autoimmune Diseases, Chronic Diseases, Blood Disorders, Growth Hormone Deficiencies, Infectious Diseases, Type II Diabetes, Obesity, and Other Indications), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa).
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the biosimilars market. A detailed analysis of key industry players has been conducted to provide insights into their business overviews, products, solutions, key strategies, collaborations, partnerships, and agreements.
Key Benefits of Buying the Report:
The report will help market leaders and new entrants by providing the closest approximations of revenue for the overall biosimilars market and its subsegments. It will also help stakeholders better understand the competitive landscape, gain more insights into better positioning of their businesses, and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on key drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
・Analysis of key drivers (Patent expiry of blockbuster biologics, Healthcare cost-containment & favorable reimbursement policies, Increasing physician & patient acceptance of biosimilars, Regulatory harmonization & faster biosimilar approval pathways), restraints (Price erosion due to intense biosimilar competition, High development & manufacturing costs, Regulatory complexity across emerging markets, Limited physician confidence in certain regions), opportunities (Next-wave patent expiries of high-value biologics, Expansion into emerging markets, Interchangeability & automatic pharmacy substitution, Government incentives for domestic biologics manufacturing), and challenges (Intensifying competition among biosimilar manufacturers, Originator lifecycle management strategies, Manufacturing capacity & supply chain complexity).
・Product Development/Innovation: Detailed insights into upcoming technologies and research & development activities in the biosimilars market.
・Market Development: Comprehensive information about lucrative markets. The report analyses the market across varied regions.
・Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the biosimilars market.
・Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been carried out to provide insights into their key strategies, product launches/approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investments & funding activities, brand/product comparative analysis, and vendor valuation & financial metrics of the biosimilars market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 37
1.1 STUDY OBJECTIVES 37
1.2 MARKET DEFINITION 38
1.3 INCLUSIONS AND EXCLUSIONS 38
1.4 STUDY SCOPE 39
1.4.1 SEGMENTS CONSIDERED 39
1.4.2 YEARS CONSIDERED 40
1.4.3 CURRENCY CONSIDERED 40
1.5 STAKEHOLDERS 40
1.6 SUMMARY OF CHANGES 41
2 EXECUTIVE SUMMARY 42
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 42
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 44
2.3 DISRUPTIVE TRENDS IN BIOSIMILARS MARKET 45
2.4 HIGH-GROWTH SEGMENTS 46
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 47
3 PREMIUM INSIGHTS 49
3.1 BIOSIMILARS MARKET OVERVIEW 49
3.2 NORTH AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS 50
3.3 BIOSIMILARS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 51
3.4 BIOSIMILARS MARKET SHARE, BY INDICATION, 2026 VS. 2036 (%) 51
4 MARKET OVERVIEW 52
4.1 INTRODUCTION 52
4.2 MARKET DYNAMICS 52
4.2.1 DRIVERS 53
4.2.1.1 Patent Expiry of Blockbuster Biologics 53
4.2.1.2 Healthcare Cost-Containment and Favorable Reimbursement Policies 54
4.2.1.3 Increasing Physician and Patient Acceptance of Biosimilars 54
4.2.1.4 Regulatory Harmonization and Faster Biosimilar Approval Pathways 55
4.2.2 RESTRAINTS 55
4.2.2.1 Price Erosion Due to Intense Biosimilar Competition 55
4.2.2.2 High Development and Manufacturing Costs 56
4.2.2.3 Regulatory Complexity Across Emerging Markets 56
4.2.2.4 Limited Physician Confidence in Certain Regions 56
4.2.3 OPPORTUNITIES 57
4.2.3.1 Next-Wave Patent Expiries of High-Value Biologics 57
4.2.3.2 Expansion into Emerging Markets 57
4.2.3.3 Interchangeability & Automatic Pharmacy Substitution 58
4.2.3.4 Government Incentives for Domestic Biologics Manufacturing 58
4.2.4 CHALLENGES 59
4.2.4.1 Intensifying Competition Among Biosimilar Manufacturers 59
4.2.4.2 Originator Lifecycle Management Strategies 59
4.2.4.3 Manufacturing Capacity & Supply Chain Complexity 59
4.3 UNMET NEEDS & WHITE SPACES 60
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 61
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 63
5 INDUSTRY TRENDS 65
5.1 PORTER’S FIVE FORCES ANALYSIS 65
5.1.1 THREAT OF NEW ENTRANTS 66
5.1.2 THREAT OF SUBSTITUTES 66
5.1.3 BARGAINING POWER OF BUYERS 66
5.1.4 BARGAINING POWER OF SUPPLIERS 66
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 67
5.2 MACROECONOMIC OUTLOOK 67
5.2.1 INTRODUCTION 67
5.2.2 GDP TRENDS AND FORECAST 67
5.2.3 TRENDS IN GLOBAL BIOSIMILARS MARKET 67
5.2.4 TRENDS IN HEALTHCARE EXPENDITURE 68
5.3 VALUE CHAIN ANALYSIS 70
5.4 SUPPLY CHAIN ANALYSIS 71
5.5 ECOSYSTEM ANALYSIS 73
5.5.1 EMERGING BUSINESS MODELS AND ECOSYSTEM SHIFTS 75
5.6 PRICING ANALYSIS 75
5.6.1 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS, BY KEY PLAYER, 2023–2025 76
5.6.2 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS, BY REGION, 2023–2025 77
5.7 KEY CONFERENCES & EVENTS 79
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 80
5.9 INVESTMENT/FUNDING ACTIVITY 81
5.10 CASE STUDY ANALYSIS 82
5.11 IMPACT OF 2025 US TARIFF ON BIOSIMILARS MARKET 84
5.11.1 INTRODUCTION 84
5.11.2 KEY TARIFF RATES 84
5.11.3 PRICE IMPACT ANALYSIS 85
5.11.4 IMPACT ON COUNTRY/REGION 86
5.11.4.1 North America 86
5.11.4.1.1 US 86
5.11.4.2 Europe 86
5.11.4.3 Asia Pacific 87
5.11.5 IMPACT ON UPSTREAM MANUFACTURING INDUSTRIES 87
5.12 PIPELINE ANALYSIS 88
5.12.1 BIOSIMILAR PRODUCTS IN CLINICAL PIPELINE 88
5.13 LIST OF KEY BIOLOGICS TO GO OFF-PATENT 89
5.14 LIST OF BIOSIMILARS MANUFACTURING FACILITIES, BY KEY PLAYER 91
5.15 MANUFACTURING FACILITY EXPANSION 93
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 96
6.1 TECHNOLOGY ANALYSIS 96
6.1.1 KEY TECHNOLOGIES 96
6.1.1.1 Advanced bioprocessing & manufacturing technologies 96
6.1.1.2 Analytical & characterization techniques 96
6.1.2 COMPLEMENTARY TECHNOLOGIES 97
6.1.2.1 AI & ML 97
6.1.2.2 Lab automation & robotics 97
6.1.3 ADJACENT TECHNOLOGIES 97
6.1.3.1 Microbial fermentation 97
6.1.3.2 3D bioprinting & high-density cell culture 98
6.2 FUTURE APPLICATIONS 99
6.3 IMPACT OF AI/GEN AI ON BIOSIMILARS MARKET 100
6.3.1 TOP USE CASES AND MARKET POTENTIAL 100
6.3.1.1 Accelerated Drug Development and Reduced Costs 100
6.3.1.2 Enhanced Manufacturing and Quality Control 100
6.3.1.3 Smarter Commercialization and Regulatory Strategy 101
6.3.2 CASE STUDIES OF AI IMPLEMENTATION IN BIOSIMILARS MARKET 101
6.3.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 102
6.3.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN BIOSIMILARS MARKET 102
6.4 SUCCESS STORIES AND REAL-WORLD APPLICATIONS 103
7 SUSTAINABILITY AND REGULATORY LANDSCAPE 104
7.1 REGIONAL REGULATIONS AND COMPLIANCE 104
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105
7.1.2 REGULATORY FRAMEWORK 107
7.2 REIMBURSEMENT SCENARIO ANALYSIS 109
7.2.1 INDUSTRY STANDARDS 114
7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 116
7.4 CERTIFICATIONS, LABELING, & ECO-STANDARDS 117
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 118
8.1 DECISION-MAKING PROCESS 118
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 118
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 118
8.2.2 KEY BUYING CRITERIA, BY END USER 120
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 121
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 123
8.5 MARKET PROFITABILITY 124
9 BIOSIMILARS MARKET, BY DRUG CLASS 125
9.1 INTRODUCTION 126
9.2 MONOCLONAL ANTIBODIES 126
9.2.1 RITUXIMAB 131
9.2.1.1 Increasing cancer and autoimmune disease burden, coupled with expanding biosimilar competition, to support market growth 131
9.2.2 INFLIXIMAB 134
9.2.2.1 Loss of patent exclusivity to fuel adoption of Infliximab for treating autoimmune diseases 134
9.2.3 ADALIMUMAB 137
9.2.3.1 Cost-effectiveness and improved patient access to fuel segment growth 137
9.2.4 TRASTUZUMAB 140
9.2.4.1 Rising incidence of breast cancer to support market growth 140
9.2.5 PEMBROLIZUMAB 143
9.2.5.1 High-value oncology opportunity driven by Keytruda’s patent expiry and strong biosimilar pipeline 143
9.2.6 DUPILUMAB 146
9.2.6.1 Broad indication base and blockbuster sales make dupilumab high-value next-wave biosimilar opportunity 146
9.2.7 USTEKINUMAB 149
9.2.7.1 Highly competitive biosimilars market, with multiple products commercialized across major regions 149
9.2.8 RISANKIZUMAB 151
9.2.8.1 Rapidly growing Skyrizi sales and broad inflammatory-disease footprint make risankizumab major future biosimilar opportunity 151
9.2.9 DARATUMUMAB 154
9.2.9.1 High-value oncology franchise and expanding multiple myeloma use make daratumumab major future biosimilar opportunity 154
9.2.10 NIVOLUMAB 157
9.2.10.1 Large oncology revenue base and broad tumor coverage make nivolumab important future checkpoint 157
9.2.11 OTHER MONOCLONAL ANTIBODIES 159
9.3 GRANULOCYTE COLONY-STIMULATING FACTOR 164
9.3.1 MATURE COMMERCIALIZATION AND ESTABLISHED BIOSIMILAR ADOPTION MAKE G-CSF HIGH-VOLUME, PRICE-COMPETITIVE BIOSIMILAR SEGMENT 164
9.4 INSULIN 168
9.4.1 HIGH PREVALENCE OF DIABETES TO BOOST MARKET GROWTH 168
9.5 ERYTHROPOIETIN 171
9.5.1 RISING INCIDENCE OF BLOOD DISORDERS TO AUGMENT MARKET GROWTH 171
9.6 RECOMBINANT HUMAN GROWTH HORMONE 175
9.6.1 RISING INCIDENCE OF GROWTH DEFICIENCY DISORDERS IN ADULTS AND CHILDREN TO PROPEL MARKET GROWTH 175
9.7 ETANERCEPT 178
9.7.1 APPROVAL AND COMMERCIALIZATION OF ETANERCEPT BIOSIMILARS TO ACCELERATE MARKET EXPANSION 178
9.8 FOLLITROPIN 181
9.8.1 POPULARITY OF FOLLITROPIN IN INFERTILITY TREATMENT TO SPUR MARKET GROWTH 181
9.9 TERIPARATIDE 184
9.9.1 INCREASING INCIDENCE OF OSTEOPOROSIS TO BOOST DEMAND 184
9.10 INTERFERONS 187
9.10.1 GROWING PREVALENCE OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH 187
9.11 ANTICOAGULANTS 191
9.11.1 RISING PREVALENCE OF CARDIOVASCULAR DISEASES TO FUEL MARKET GROWTH 191
9.12 AFLIBERCEPT 194
9.12.1 LARGE OPHTHALMOLOGY MARKET AND RAPID BIOSIMILAR UPTAKE ARE MAKING AFLIBERCEPT KEY COMMERCIAL BIOSIMILAR SEGMENT 194
9.13 GLP-1 AGONIST 198
9.13.1 HIGH PREVALENCE OF DIABETES AND OBESITY TO AID MARKET GROWTH 198
9.14 OTHER DRUG CLASSES 202
10 BIOSIMILARS MARKET, BY INDICATION 205
10.1 INTRODUCTION 206
10.2 ONCOLOGY 206
10.2.1 INCREASED APPROVALS AND LAUNCH OF BIOSIMILARS FOR CANCER TO DRIVE MARKET 206
10.3 INFLAMMATORY & AUTOIMMUNE DISEASES 210
10.3.1 CHANGES IN LIFESTYLES AND ENVIRONMENTAL CONDITIONS LEAD TO INCREASING INCIDENCES OF INFLAMMATORY AND AUTOIMMUNE DISEASES 210
10.4 CHRONIC DISEASES 213
10.4.1 HIGH BURDEN OF CVD WORLDWIDE TO DRIVE MARKET GROWTH 213
10.5 BLOOD DISORDERS 217
10.5.1 INCREASING INCIDENCE OF BLOOD DISORDERS TO BOOST BIOSIMILAR DEMAND 217
10.6 GROWTH HORMONE DEFICIENCY 220
10.6.1 RISING USE OF BIOSIMILARS FOR TREATMENT OF GHD 220
10.7 INFECTIOUS DISEASES 224
10.7.1 BIOSIMILARS MARKET FOR INFECTIOUS DISEASES TO GROW RAPIDLY IN ASIA PACIFIC 224
10.8 TYPE II DIABETES 227
10.8.1 RISING PREVALENCE OF DIABETES PROPELS MARKET GROWTH 227
10.9 OBESITY 231
10.9.1 DEVELOPMENT OF GLP-1 ANTAGONIST BIOSIMILARS PROPELS MARKET GROWTH 231
10.10 OTHER INDICATIONS 234
11 BIOSIMILARS MARKET, BY REGION 238
11.1 INTRODUCTION 239
11.2 NORTH AMERICA 239
11.2.1 US 242
11.2.1.1 US to dominate North American biosimilars market 242
11.2.2 CANADA 246
11.2.2.1 Favorable government initiatives to support market 246
11.3 EUROPE 250
11.3.1 GERMANY 256
11.3.1.1 Germany to dominate European biosimilars market 256
11.3.2 UK 258
11.3.2.1 Increasing adoption of biosimilars to boost market 258
11.3.3 FRANCE 261
11.3.3.1 Rising geriatric population to drive market growth 261
11.3.4 ITALY 263
11.3.4.1 Favorable government policies to propel adoption of biosimilars 263
11.3.5 SPAIN 266
11.3.5.1 Favorable patient incentives to promote biosimilar use 266
11.3.6 REST OF EUROPE 269
11.4 ASIA PACIFIC 271
11.4.1 CHINA 274
11.4.1.1 China to register fastest growth in Asia Pacific market 274
11.4.2 JAPAN 277
11.4.2.1 Large geriatric population to drive market growth 277
11.4.3 INDIA 280
11.4.3.1 Increasing biosimilar launches and approvals to support market growth 280
11.4.4 SOUTH KOREA 283
11.4.4.1 Favorable government initiatives to support growth 283
11.4.5 AUSTRALIA 285
11.4.5.1 Favorable regulatory changes and increasing disease incidence to propel growth 285
11.4.6 REST OF ASIA PACIFIC 288
11.5 LATIN AMERICA 290
11.5.1 BRAZIL 293
11.5.1.1 Increased government investments in pharmaceutical R&D to drive market 293
11.5.2 MEXICO 296
11.5.2.1 Rising demand for chronic disease treatment to support market growth 296
11.5.3 REST OF LATIN AMERICA 299
11.6 MIDDLE EAST 301
11.6.1 GCC COUNTRIES 304
11.6.1.1 Saudi Arabia 307
11.6.1.1.1 Centralized procurement, localization policies, and increasingly biosimilar-supportive regulatory framework to accelerate biosimilar adoption in Saudi Arabia 307
11.6.1.2 UAE 309
11.6.1.2.1 Rapid expansion of advanced healthcare infrastructure combined with payer pressure to reduce biologic treatment costs is strengthening commercial case for biosimilars in UAE 309
11.6.1.3 Rest of GCC 311
11.6.2 REST OF MIDDLE EAST 313
11.7 AFRICA 315
12 COMPETITIVE LANDSCAPE 317
12.1 OVERVIEW 317
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 317
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOSIMILARS MARKET, 2024−2026 317
12.3 REVENUE ANALYSIS, 2023-2025 319
12.4 MARKET SHARE ANALYSIS, 2025 320
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 322
12.5.1 STARS 323
12.5.2 EMERGING LEADERS 323
12.5.3 PERVASIVE PLAYERS 323
12.5.4 PARTICIPANTS 323
12.6 COMPETITIVE BENCHMARKING OF TOP PLAYERS 325
12.6.1 COMPANY FOOTPRINT 325
12.6.2 REGION FOOTPRINT 326
12.6.3 DRUG CLASS FOOTPRINT 327
12.6.4 INDICATION FOOTPRINT 328
12.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 329
12.7.1 PROGRESSIVE COMPANIES 329
12.7.2 RESPONSIVE COMPANIES 329
12.7.3 DYNAMIC COMPANIES 329
12.7.4 STARTING BLOCKS 329
12.8 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 331
12.9 VALUATION AND FINANCIAL METRICS OF BIOSIMILAR VENDORS 333
12.9.1 FINANCIAL METRICS 333
12.9.2 COMPANY VALUATION 333
12.10 BRAND/PRODUCT COMPARISON 334
12.11 COMPETITIVE SCENARIO 335
12.11.1 PRODUCT APPROVALS 335
12.11.2 DEALS 336
12.11.3 EXPANSIONS 337
13 COMPANY PROFILES 338
13.1 KEY PLAYERS 338
13.1.1 SANDOZ GROUP AG 338
13.1.1.1 Products offered 340
13.1.1.2 Products in pipeline 340
13.1.1.3 Recent developments 341
13.1.1.3.1 Product launches and approvals 341
13.1.1.3.2 Deals 342
13.1.1.3.3 Expansions 343
13.1.1.3.4 Other developments 343
13.1.1.4 MnM view 343
13.1.1.4.1 Key strengths 343
13.1.1.4.2 Strategic choices 343
13.1.1.4.3 Weaknesses & competitive threats 344
13.1.2 AMGEN INC. 345
13.1.2.1 Products offered 347
13.1.2.2 Products in pipeline 347
13.1.2.3 Recent developments 348
13.1.2.3.1 Product launches and approvals 348
13.1.2.3.2 Deals 348
13.1.2.3.3 Expansions 349
13.1.2.4 MnM view 349
13.1.2.4.1 Key strengths 349
13.1.2.4.2 Strategic choices 350
13.1.2.4.3 Weaknesses & competitive threats 350
13.1.3 CELLTRION INC. 351
13.1.3.1 Products offered 353
13.1.3.2 Recent developments 354
13.1.3.2.1 Product launches and approvals 354
13.1.3.2.2 Deals 355
13.1.3.2.3 Expansions 355
13.1.3.3 MnM view 356
13.1.3.3.1 Key strengths 356
13.1.3.3.2 Strategic choices 356
13.1.3.3.3 Weaknesses & competitive threats 356
13.1.4 PFIZER INC. 357
13.1.4.1 Business overview 357
13.1.4.2 Products offered 358
13.1.4.3 Recent developments 359
13.1.4.3.1 Product approvals 359
13.1.4.3.2 Deals 360
13.1.4.4 MnM view 360
13.1.4.4.1 Key strengths 360
13.1.4.4.2 Strategic choices 360
13.1.4.4.3 Weaknesses & competitive threats 361
13.1.5 BIOCON 362
13.1.5.1 Business overview 362
13.1.5.2 Products offered 364
13.1.5.3 Recent developments 365
13.1.5.3.1 Product approvals 365
13.1.5.3.2 Deals 366
13.1.5.3.3 Other developments 366
13.1.5.4 MnM view 367
13.1.5.4.1 Key strengths 367
13.1.5.4.2 Strategic choices 367
13.1.5.4.3 Weaknesses & competitive threats 367
13.1.6 DR. REDDY’S LABORATORIES LTD. 368
13.1.6.1 Products offered 369
13.1.6.2 Recent developments 370
13.1.6.2.1 Product launches 370
13.1.6.2.2 Deals 370
13.1.6.2.3 Other developments 371
13.1.7 ELI LILLY AND COMPANY 372
13.1.7.1 Products offered 373
13.1.7.2 Recent developments 374
13.1.7.2.1 Product launches 374
13.1.7.2.2 Deals 374
13.1.7.2.3 Expansions 374
13.1.8 TEVA PHARMACEUTICAL INDUSTRIES LTD. 375
13.1.8.1 Products offered 376
13.1.8.2 Recent developments 376
13.1.8.2.1 Product launches and approvals 376
13.1.8.2.2 Deals 377
13.1.8.2.3 Other developments 378
13.1.9 FRESENIUS KABI AG 379
13.1.9.1 Products offered 380
13.1.9.2 Recent developments 381
13.1.9.2.1 Product Launches and Approvals 381
13.1.9.2.2 Deals 382
13.1.9.2.3 Other developments 382
13.1.10 STADA ARZNEIMITTEL AG 383
13.1.10.1 Products offered 384
13.1.10.2 Recent developments 385
13.1.10.2.1 Product launches/Approvals 385
13.1.10.2.2 Deals 386
13.1.10.2.3 Expansions 387
13.1.10.2.4 Other developments 387
13.1.11 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 388
13.1.11.1 Products offered 389
13.1.11.2 Recent developments 390
13.1.11.2.1 Product approvals 390
13.1.11.2.2 Deals 390
13.1.11.2.3 Expansions 390
13.1.12 SAMSUNG BIOEPIS HOLDINGS CO., LTD. 391
13.1.12.1 Business overview 391
13.1.12.2 Products offered 392
13.1.12.3 Recent developments 394
13.1.12.3.1 Product Launches and Approvals 394
13.1.12.3.2 Deals 395
13.1.13 AMNEAL PHARMACEUTICALS LLC 396
13.1.13.1 Business overview 396
13.1.13.2 Products offered 397
13.1.13.3 Recent developments 397
13.1.13.3.1 Product approvals 397
13.1.13.3.2 Deals 398
13.1.13.3.3 Other developments 398
13.1.14 BIO THERA SOLUTIONS 399
13.1.14.1 Business overview 399
13.1.14.2 Products offered 400
13.1.14.3 Recent developments 400
13.1.14.3.1 Product approvals 400
13.1.14.3.2 Deals 401
13.1.15 APROGEN 402
13.1.15.1 Business overview 402
13.1.15.2 Products offered 402
13.1.15.3 Recent developments 402
13.1.15.3.1 Product approvals 402
13.1.15.4 Products in pipeline 403
13.1.16 SHANGHAI HENLIUS BIOTECH, INC. 404
13.1.16.1 Business overview 404
13.1.16.2 Products offered 405
13.1.16.3 Products in pipeline 405
13.1.16.4 Recent developments 406
13.1.16.4.1 Product approvals 406
13.1.16.4.2 Deals 406
13.1.16.4.3 Other developments 407
13.1.17 ALVOTECH 408
13.1.17.1 Business overview 408
13.1.17.2 Products offered 409
13.1.17.3 Products in pipeline 410
13.1.17.4 Recent developments 410
13.1.17.4.1 Product approvals 410
13.1.17.4.2 Deals 411
13.2 OTHER PLAYERS 413
13.2.1 AMEGA BIOTECH 413
13.2.2 BIOCAD 414
13.2.3 PROBIOMED S.A. DE C.V. 414
13.2.4 FUJIFILM KYOWA KIRIN BIOLOGICS CO., LTD. 415
13.2.5 POLPHARMA BIOLOGICS GROUP 416
13.2.6 NEUCLONE 417
13.2.7 XENTRIA 418
13.2.8 NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC 419
13.2.9 SYNERMORE BIOLOGICS (SUZHOU) CO., LTD. 420
13.2.10 CURATEQ BIOLOGICS PVT. LTD. 421
13.2.11 XBRANE BIOPHARMA AB 422
13.2.12 FORMYCON AG 423
13.2.13 SAM CHUN DANG PHARM. CO., LTD. 424
13.2.14 PRESTIGE BIOPHARMA 425
13.2.15 BIOEQ AG 426
14 RESEARCH METHODOLOGY 427
14.1 RESEARCH DATA 427
14.1.1 SECONDARY DATA 428
14.1.1.1 Key data from secondary sources 429
14.1.2 PRIMARY DATA 429
14.2 MARKET ESTIMATION METHODOLOGY 431
14.2.1 GLOBAL MARKET ESTIMATION 431
14.2.2 INSIGHTS OF PRIMARY EXPERTS 433
14.2.3 SEGMENTAL MARKET SIZE ESTIMATION 434
14.3 MARKET GROWTH RATE PROJECTIONS 435
14.4 MARKET BREAKDOWN AND DATA TRIANGULATION 436
14.5 RESEARCH ASSUMPTIONS 437
14.6 RESEARCH LIMITATIONS 438
14.7 RISK ANALYSIS 438
15 APPENDIX 439
15.1 DISCUSSION GUIDE 439
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 443
15.3 CUSTOMIZATION OPTIONS 445
15.4 RELATED REPORTS 446
15.5 AUTHOR DETAILS 447